查看購物車
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1964075

氫可酮藥物市場－全球產業規模、佔有率、趨勢、機會、預測：按產品、應用、地區和競爭對手分類，2021-2031年

Morphine Drugs Market- Global Industry Size, Share, Trends, Opportunity, and Forecast, Segmented By Product, By Application, By Region & Competition, 2021-2031F
出版日期: | 出版商: TechSci Research | 英文 180 Pages | 商品交期: 2-3個工作天內

價格

We offer 8 hour analyst time for an additional research. Please contact us for the details.

簡介目錄

全球氫可酮藥品市場預計將從 2025 年的 267.8 億美元成長到 2031 年的 358.1 億美元，複合年成長率為 4.96%。

氫可酮是一種從罌粟提取的強效鴉片類鎮痛藥，是治療方法嚴重急性和慢性疼痛的基礎藥物，尤其是在安寧療護和癌症治療領域。慢性疾病在全球日益加重，老齡化社會對永續疼痛管理策略的需求不斷成長，以及安寧療護服務在國際醫療體系中的重要性日益凸顯，這些因素共同推動了嗎啡市場的成長，鞏固了其作為標準治療藥物的地位。

市場概覽
預測期 2027-2031
市場規模：2025年 267.8億美元
市場規模：2031年 358.1億美元
複合年成長率：2026-2031年 4.96%
成長最快的細分市場 緩解疼痛
最大的市場 北美洲

另一方面，全球對鴉片類藥物成癮和濫用問題的擔憂，導致嚴格的法規結構和供應鏈失衡，這給市場擴張帶來了重大障礙。這些監管壁壘造成許多地區的生產能力與患者供應之間存在缺口，限制了患者獲得藥物的機會。根據國際麻醉藥品管制局的數據，到2025年，全球生產的氫可酮中只有18%將直接用於鎮痛，凸顯了用於基本醫療的嗎啡生產能力嚴重不足。

市場促進因素

慢性疼痛和癌症發生率的上升是全球氫可酮藥物市場的主要驅動力，導致對鴉片類鎮痛藥的需求迫切增加。隨著惡性腫瘤發生率的上升，尤其是在篩檢率高的已開發國家，對積極疼痛管理通訊協定和藥用級氫可酮的需求持續成長。例如，美國癌症協會於2025年1月發布的《2025年癌症事實與數據》報告預測，光是在美國，每年新增癌症病例就將超過200萬例。為了滿足不斷成長的臨床需求，主要生產商正在提高產量。 Hikma Pharmaceuticals在其2025年2月發布的中期財務報告中指出，其2024年注射劑銷售額成長9%，達到13.06億美元，反映出重症監護領域的強勁成長勢頭。

同時，對安寧療護和臨終關懷服務的需求不斷成長，推動了市場發展，其關注點正轉向以舒適為導向的干涉措施，而氫可酮仍然是臨終疼痛管理的黃金標準。儘管臨終關懷機構已融入醫療保健基礎設施，但安寧療護的需求與其可近性之間仍存在顯著差距。根據國際麻醉藥品管制局 (INCB) 年度報告的分析（該報告由國際藥物政策聯盟 (IDPC) 於 2025 年 6 月發布），全球僅有 33,547 公斤氫可酮用於安寧療護，遠低於估計的最低合理消費量 43,000 公斤。這種差距為能夠克服監管複雜性以滿足這一未被滿足的需求的供應商帶來了巨大的商機。

市場挑戰

為防止鴉片類藥物濫用而建立的嚴格法規結構，是氫可酮市場擴張的主要障礙。這些法規帶來了複雜的合規負擔，並使供應鏈更加複雜，導致氫可酮的分銷對生產商而言既困難又成本高昂。儘管其目的是為了預防成癮，但卻造成了僵化的貿易環境，使得必要的鎮痛藥分銷經常出現延誤或中斷。因此，生產者無法有效地服務臨床需求高的地區，導致收入成長停滯，並在安寧療護需求日益成長的地區阻礙了市場滲透。

這些限制性政策造成了全球醫療保健需求與實際產品供應之間的嚴重失衡。優先控制而非可及性意味著，即使生產能力充足，產品也常常無法送達患者手中。國際麻醉品管制局（INCB）近期發布的經銷資料印證了這項物流瓶頸。該局報告稱，到2024年，全球約78%的人口居住在經銷法律限制鴉片類止痛藥取得的國家。這項數據凸顯了監管障礙如何透過人為抑制消費直接阻礙市場規模的擴大。

市場趨勢

全球氫可酮市場正因新型植入式和鞘內給藥系統的出現而重組。這些系統為頑固性疼痛提供了標靶治療方案。臨床醫師越來越避免全身給藥，轉而直接鞘內注射氫可酮，從而在最大限度減少副作用的同時，最佳化惡性疼痛的療效。可程式設計泵浦技術在長期給藥方面的應用也推動了這項轉變。根據Medtronic2025年6月發布的《2024年標靶藥物輸送系統產品性能報告》，該公司註冊登記系統追蹤了10,793名使用這些系統的患者，其中17.0%的植入專門用於治療惡性疼痛。這表明，對於複雜的癌症疾病，人們越來越依賴先進的給藥機制。

同時，居家臨終關懷中氫可酮使用量的增加顯著穩定了其供應。隨著醫療保健系統將臨終關懷分散化，氫可酮仍然是臨終關懷中必不可少的治療藥物，監管機構正被敦促保護其供應。與其他因濫用擔憂而面臨減產的鴉片類藥物不同，氫可酮的配額得以維持，以確保居家病患的持續供應。美國緝毒局（DEA）於2024年12月發布的「2025會計年度總生產配額」維持了氫可酮的生產配額不變，以滿足合法的醫療需求。同時，其他鴉片類藥物（例如羥考酮）的配額有所減少，這凸顯了氫可酮在不斷發展的居家醫療領域中的關鍵作用。

目錄

第1章概述

第2章：調查方法

第3章執行摘要

第4章：客戶心聲

第5章：全球氫可酮藥物市場展望

  • 市場規模及預測
    • 按金額
  • 市佔率及預測
    • 產品特定型鴉片類藥物（即時釋/短效鴉片類藥物、緩釋/長效型鴉片類藥物）
    • 應用範圍（緩解疼痛、麻醉、止咳、止瀉、成癮治療）
    • 按地區
    • 按公司（2025 年）
  • 市場地圖

第6章：北美氫可酮藥物市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 北美洲：國別分析
    • 美國
    • 加拿大
    • 墨西哥

第7章：歐洲氫可酮藥物市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 歐洲：國別分析
    • 德國
    • 法國
    • 英國
    • 義大利
    • 西班牙

第8章：亞太地區氫可酮藥物市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 亞太地區：國別分析
    • 中國
    • 印度
    • 日本
    • 韓國
    • 澳洲

第9章：中東和非洲氫可酮藥物市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 中東與非洲：國別分析
    • 沙烏地阿拉伯
    • 阿拉伯聯合大公國
    • 南非

第10章：南美洲氫可酮藥物市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 南美洲：國別分析
    • 巴西
    • 哥倫比亞
    • 阿根廷

第11章 市場動態

  • 促進因素
  • 任務

第12章 市場趨勢與發展

  • 併購
  • 產品發布
  • 近期趨勢

第13章：全球氫可酮藥物市場：SWOT分析

第14章：波特五力分析

  • 產業競爭
  • 新進入者的潛力
  • 供應商的議價能力
  • 顧客權力
  • 替代品的威脅

第15章 競爭格局

  • Hikma Pharmaceuticals plc
  • Pfizer Inc.
  • AbbVie Inc.
  • Sanofi SA
  • Viatris Inc.
  • Sun Pharmaceutical Industries Ltd.
  • Teva Pharmaceutical Industries Ltd.
  • Endo, Inc.
  • Verve Health Care Ltd.
  • Mallinckrodt Pharmaceuticals

第16章 策略建議

第17章：關於研究公司及免責聲明

簡介目錄
Product Code: 23843

The Global Morphine Drugs Market is projected to expand from USD 26.78 Billion in 2025 to USD 35.81 Billion by 2031, reflecting a CAGR of 4.96%. Morphine, a potent opioid analgesic derived from the opium poppy, serves as a fundamental treatment for severe acute and chronic pain, particularly within palliative and cancer care environments. This market growth is underpinned by the increasing global burden of chronic diseases and an aging population that necessitates consistent pain management strategies, alongside a growing emphasis on palliative care services within international healthcare systems that solidifies the drug's status as a standard of care.

Market Overview
Forecast Period2027-2031
Market Size 2025USD 26.78 Billion
Market Size 2031USD 35.81 Billion
CAGR 2026-20314.96%
Fastest Growing SegmentPain Relief
Largest MarketNorth America

Conversely, market expansion faces significant hurdles due to strict regulatory frameworks and supply chain disparities stemming from global concerns regarding opioid addiction and misuse. These regulatory barriers often limit accessibility, creating a disconnect between manufacturing capabilities and patient availability across many regions. Data from the International Narcotics Control Board indicates that in 2025, only 18 percent of globally manufactured morphine was utilized directly for pain relief, highlighting a severe underutilization of production capacity intended for essential medical treatment.

Market Driver

The escalating prevalence of chronic pain and cancer serves as a primary catalyst for the Global Morphine Drugs Market, creating an urgent need for increased opioid analgesic production. As the incidence of malignant neoplasms rises, particularly in developed nations with high detection rates, the demand for aggressive pain management protocols and pharmaceutical-grade morphine continues to intensify. For instance, the American Cancer Society's 'Cancer Facts & Figures 2025' report from January 2025 projects over 2 million new cancer diagnoses in the United States alone for the year. To meet these growing clinical requirements, major manufacturers are scaling up operations; Hikma Pharmaceuticals reported in their February 2025 preliminary results that their Injectables business revenue grew by 9 percent to $1.306 billion in 2024, reflecting robust activity in the critical care sector.

Simultaneously, the rising demand for palliative and end-of-life care services propels market momentum, shifting focus toward comfort-oriented interventions where morphine remains the gold standard for terminal pain. Despite the integration of hospice units into healthcare infrastructures, a distinct gap persists between palliative necessity and accessibility. According to a June 2025 analysis by the International Drug Policy Consortium referencing the annual INCB report, only 33,547 kilograms of morphine are utilized globally for palliative care, falling short of the estimated 43,000 kilograms required for minimally adequate consumption. This disparity highlights a substantial opportunity for suppliers capable of navigating regulatory complexities to meet this unmet demand.

Market Challenge

Stringent regulatory frameworks established to mitigate opioid misuse act as a primary obstruction to the expansion of the morphine market. These regulations impose complex compliance burdens that complicate the supply chain, making the distribution of morphine administratively difficult and costly for manufacturers. Although the intent is to prevent addiction, the practical result is a rigid trade environment where the movement of essential analgesics is frequently delayed or halted. Consequently, manufacturers are prevented from effectively serving regions with high clinical demand, thereby capping revenue growth and stifling market penetration in areas where palliative care needs are rising.

The impact of these restrictive policies leads to a severe imbalance between global medical needs and actual product availability. The prioritization of control over accessibility means that despite adequate manufacturing capabilities, the product often fails to reach the patient base. This logistical bottleneck is substantiated by recent distribution data from the International Narcotics Control Board, which reported in 2024 that approximately 78 percent of the global population lived in countries with inadequate access to opioid analgesics due to restrictive distribution laws. This statistic underscores how regulatory barriers directly hamper market volume by artificially suppressing consumption rates.

Market Trends

The Global Morphine Drugs Market is being reshaped by the emergence of novel implantable and intrathecal delivery systems, which provide targeted alternatives for refractory pain. Clinicians are increasingly bypassing systemic administration to deliver morphine directly to the intrathecal space, optimizing efficacy for malignant pain while minimizing adverse effects, a shift supported by the adoption of programmable pump technologies for long-term dosing. According to Medtronic's June 2025 'Targeted Drug Delivery Systems 2024 Product Performance Report', the company's registry tracked 10,793 patients utilizing these systems, with 17.0 percent of implants specifically indicated for the treatment of malignant pain, underscoring the growing reliance on sophisticated delivery mechanisms for complex cancer conditions.

Concurrently, the increasing utilization of morphine in home-based palliative care settings is driving a distinct stabilization in supply. As healthcare systems decentralize end-of-life treatment, morphine remains the essential therapeutic agent for hospice care, prompting regulatory bodies to protect its availability. Unlike other opioids facing production cuts due to misuse concerns, morphine quotas are being maintained to ensure continuity for patients in home-based settings. The Drug Enforcement Administration's '2025 Aggregate Production Quotas', released in December 2024, kept the production quota for morphine unchanged to meet legitimate medical needs, whereas quotas for other opioids like oxycodone were reduced, highlighting the critical role of morphine in the expanding home-care sector.

Key Market Players

  • Hikma Pharmaceuticals plc
  • Pfizer Inc.
  • AbbVie Inc.
  • Sanofi S.A
  • Viatris Inc.
  • Sun Pharmaceutical Industries Ltd.
  • Teva Pharmaceutical Industries Ltd.
  • Endo, Inc.
  • Verve Health Care Ltd.
  • Mallinckrodt Pharmaceuticals

Report Scope

In this report, the Global Morphine Drugs Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Morphine Drugs Market, By Product

  • Immediate Release/ Short Acting Opioids
  • Extended Release/Long-Acting Opioids

Morphine Drugs Market, By Application

  • Pain Relief
  • Anesthesia
  • Cough Suppression
  • Diarrhoea Suppression
  • De-addiction

Morphine Drugs Market, By Region

  • North America
    • United States
    • Canada
    • Mexico
  • Europe
    • France
    • United Kingdom
    • Italy
    • Germany
    • Spain
  • Asia Pacific
    • China
    • India
    • Japan
    • Australia
    • South Korea
  • South America
    • Brazil
    • Argentina
    • Colombia
  • Middle East & Africa
    • South Africa
    • Saudi Arabia
    • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Morphine Drugs Market.

Available Customizations:

Global Morphine Drugs Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

  • Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

  • 1.1. Market Definition
  • 1.2. Scope of the Market
    • 1.2.1. Markets Covered
    • 1.2.2. Years Considered for Study
    • 1.2.3. Key Market Segmentations

2. Research Methodology

  • 2.1. Objective of the Study
  • 2.2. Baseline Methodology
  • 2.3. Key Industry Partners
  • 2.4. Major Association and Secondary Sources
  • 2.5. Forecasting Methodology
  • 2.6. Data Triangulation & Validation
  • 2.7. Assumptions and Limitations

3. Executive Summary

  • 3.1. Overview of the Market
  • 3.2. Overview of Key Market Segmentations
  • 3.3. Overview of Key Market Players
  • 3.4. Overview of Key Regions/Countries
  • 3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Global Morphine Drugs Market Outlook

  • 5.1. Market Size & Forecast
    • 5.1.1. By Value
  • 5.2. Market Share & Forecast
    • 5.2.1. By Product (Immediate Release/ Short Acting Opioids, Extended Release/Long-Acting Opioids)
    • 5.2.2. By Application (Pain Relief, Anesthesia, Cough Suppression, Diarrhoea Suppression, De-addiction)
    • 5.2.3. By Region
    • 5.2.4. By Company (2025)
  • 5.3. Market Map

6. North America Morphine Drugs Market Outlook

  • 6.1. Market Size & Forecast
    • 6.1.1. By Value
  • 6.2. Market Share & Forecast
    • 6.2.1. By Product
    • 6.2.2. By Application
    • 6.2.3. By Country
  • 6.3. North America: Country Analysis
    • 6.3.1. United States Morphine Drugs Market Outlook
      • 6.3.1.1. Market Size & Forecast
        • 6.3.1.1.1. By Value
      • 6.3.1.2. Market Share & Forecast
        • 6.3.1.2.1. By Product
        • 6.3.1.2.2. By Application
    • 6.3.2. Canada Morphine Drugs Market Outlook
      • 6.3.2.1. Market Size & Forecast
        • 6.3.2.1.1. By Value
      • 6.3.2.2. Market Share & Forecast
        • 6.3.2.2.1. By Product
        • 6.3.2.2.2. By Application
    • 6.3.3. Mexico Morphine Drugs Market Outlook
      • 6.3.3.1. Market Size & Forecast
        • 6.3.3.1.1. By Value
      • 6.3.3.2. Market Share & Forecast
        • 6.3.3.2.1. By Product
        • 6.3.3.2.2. By Application

7. Europe Morphine Drugs Market Outlook

  • 7.1. Market Size & Forecast
    • 7.1.1. By Value
  • 7.2. Market Share & Forecast
    • 7.2.1. By Product
    • 7.2.2. By Application
    • 7.2.3. By Country
  • 7.3. Europe: Country Analysis
    • 7.3.1. Germany Morphine Drugs Market Outlook
      • 7.3.1.1. Market Size & Forecast
        • 7.3.1.1.1. By Value
      • 7.3.1.2. Market Share & Forecast
        • 7.3.1.2.1. By Product
        • 7.3.1.2.2. By Application
    • 7.3.2. France Morphine Drugs Market Outlook
      • 7.3.2.1. Market Size & Forecast
        • 7.3.2.1.1. By Value
      • 7.3.2.2. Market Share & Forecast
        • 7.3.2.2.1. By Product
        • 7.3.2.2.2. By Application
    • 7.3.3. United Kingdom Morphine Drugs Market Outlook
      • 7.3.3.1. Market Size & Forecast
        • 7.3.3.1.1. By Value
      • 7.3.3.2. Market Share & Forecast
        • 7.3.3.2.1. By Product
        • 7.3.3.2.2. By Application
    • 7.3.4. Italy Morphine Drugs Market Outlook
      • 7.3.4.1. Market Size & Forecast
        • 7.3.4.1.1. By Value
      • 7.3.4.2. Market Share & Forecast
        • 7.3.4.2.1. By Product
        • 7.3.4.2.2. By Application
    • 7.3.5. Spain Morphine Drugs Market Outlook
      • 7.3.5.1. Market Size & Forecast
        • 7.3.5.1.1. By Value
      • 7.3.5.2. Market Share & Forecast
        • 7.3.5.2.1. By Product
        • 7.3.5.2.2. By Application

8. Asia Pacific Morphine Drugs Market Outlook

  • 8.1. Market Size & Forecast
    • 8.1.1. By Value
  • 8.2. Market Share & Forecast
    • 8.2.1. By Product
    • 8.2.2. By Application
    • 8.2.3. By Country
  • 8.3. Asia Pacific: Country Analysis
    • 8.3.1. China Morphine Drugs Market Outlook
      • 8.3.1.1. Market Size & Forecast
        • 8.3.1.1.1. By Value
      • 8.3.1.2. Market Share & Forecast
        • 8.3.1.2.1. By Product
        • 8.3.1.2.2. By Application
    • 8.3.2. India Morphine Drugs Market Outlook
      • 8.3.2.1. Market Size & Forecast
        • 8.3.2.1.1. By Value
      • 8.3.2.2. Market Share & Forecast
        • 8.3.2.2.1. By Product
        • 8.3.2.2.2. By Application
    • 8.3.3. Japan Morphine Drugs Market Outlook
      • 8.3.3.1. Market Size & Forecast
        • 8.3.3.1.1. By Value
      • 8.3.3.2. Market Share & Forecast
        • 8.3.3.2.1. By Product
        • 8.3.3.2.2. By Application
    • 8.3.4. South Korea Morphine Drugs Market Outlook
      • 8.3.4.1. Market Size & Forecast
        • 8.3.4.1.1. By Value
      • 8.3.4.2. Market Share & Forecast
        • 8.3.4.2.1. By Product
        • 8.3.4.2.2. By Application
    • 8.3.5. Australia Morphine Drugs Market Outlook
      • 8.3.5.1. Market Size & Forecast
        • 8.3.5.1.1. By Value
      • 8.3.5.2. Market Share & Forecast
        • 8.3.5.2.1. By Product
        • 8.3.5.2.2. By Application

9. Middle East & Africa Morphine Drugs Market Outlook

  • 9.1. Market Size & Forecast
    • 9.1.1. By Value
  • 9.2. Market Share & Forecast
    • 9.2.1. By Product
    • 9.2.2. By Application
    • 9.2.3. By Country
  • 9.3. Middle East & Africa: Country Analysis
    • 9.3.1. Saudi Arabia Morphine Drugs Market Outlook
      • 9.3.1.1. Market Size & Forecast
        • 9.3.1.1.1. By Value
      • 9.3.1.2. Market Share & Forecast
        • 9.3.1.2.1. By Product
        • 9.3.1.2.2. By Application
    • 9.3.2. UAE Morphine Drugs Market Outlook
      • 9.3.2.1. Market Size & Forecast
        • 9.3.2.1.1. By Value
      • 9.3.2.2. Market Share & Forecast
        • 9.3.2.2.1. By Product
        • 9.3.2.2.2. By Application
    • 9.3.3. South Africa Morphine Drugs Market Outlook
      • 9.3.3.1. Market Size & Forecast
        • 9.3.3.1.1. By Value
      • 9.3.3.2. Market Share & Forecast
        • 9.3.3.2.1. By Product
        • 9.3.3.2.2. By Application

10. South America Morphine Drugs Market Outlook

  • 10.1. Market Size & Forecast
    • 10.1.1. By Value
  • 10.2. Market Share & Forecast
    • 10.2.1. By Product
    • 10.2.2. By Application
    • 10.2.3. By Country
  • 10.3. South America: Country Analysis
    • 10.3.1. Brazil Morphine Drugs Market Outlook
      • 10.3.1.1. Market Size & Forecast
        • 10.3.1.1.1. By Value
      • 10.3.1.2. Market Share & Forecast
        • 10.3.1.2.1. By Product
        • 10.3.1.2.2. By Application
    • 10.3.2. Colombia Morphine Drugs Market Outlook
      • 10.3.2.1. Market Size & Forecast
        • 10.3.2.1.1. By Value
      • 10.3.2.2. Market Share & Forecast
        • 10.3.2.2.1. By Product
        • 10.3.2.2.2. By Application
    • 10.3.3. Argentina Morphine Drugs Market Outlook
      • 10.3.3.1. Market Size & Forecast
        • 10.3.3.1.1. By Value
      • 10.3.3.2. Market Share & Forecast
        • 10.3.3.2.1. By Product
        • 10.3.3.2.2. By Application

11. Market Dynamics

  • 11.1. Drivers
  • 11.2. Challenges

12. Market Trends & Developments

  • 12.1. Merger & Acquisition (If Any)
  • 12.2. Product Launches (If Any)
  • 12.3. Recent Developments

13. Global Morphine Drugs Market: SWOT Analysis

14. Porter's Five Forces Analysis

  • 14.1. Competition in the Industry
  • 14.2. Potential of New Entrants
  • 14.3. Power of Suppliers
  • 14.4. Power of Customers
  • 14.5. Threat of Substitute Products

15. Competitive Landscape

  • 15.1. Hikma Pharmaceuticals plc
    • 15.1.1. Business Overview
    • 15.1.2. Products & Services
    • 15.1.3. Recent Developments
    • 15.1.4. Key Personnel
    • 15.1.5. SWOT Analysis
  • 15.2. Pfizer Inc.
  • 15.3. AbbVie Inc.
  • 15.4. Sanofi S.A
  • 15.5. Viatris Inc.
  • 15.6. Sun Pharmaceutical Industries Ltd.
  • 15.7. Teva Pharmaceutical Industries Ltd.
  • 15.8. Endo, Inc.
  • 15.9. Verve Health Care Ltd.
  • 15.10. Mallinckrodt Pharmaceuticals

16. Strategic Recommendations

17. About Us & Disclaimer